mRNA-1273 Moderna COVID-19 Vaccine

Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination (Correspondence)
 Widge AT, Rouphael NG, Jackson LA, et al. 〔N Engl J Med. 2021 Jan 7;384(1):80-82〕(査読済み)

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
 Baden LR, El Sahly HM, Essink B, et al. 〔N Engl J Med. 2021 Feb 4;384(5):403-416〕(査読済み)

mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants
 Wu K, Werner AP, Moliva JI, et al. 〔bioRxiv. 2021 Jan 25;2021.01.25.427948〕(査読前)

Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine (correspondence)
 Wu K, Werner AP, Koch M, et al. 〔N Engl J Med. 2021 Apr 15;384(15):1468-1470〕(査読済み)

Delayed Large Local Reactions to mRNA-1273 Vaccine against SARS-CoV-2 (Correspondence)
 Blumenthal KG, Freeman EE, Saff RR, et al. 〔N Engl J Med. 2021 Apr 1;384(13):1273-1277〕(査読済み)

Neutralizing Antibodies Against SARS-CoV-2 Variants After Infection and Vaccination (Research Letter)
 Edara VV, Hudson WH, Xie X, et al. 〔JAMA. 2021 May 11;325(18):1896-1898〕(査読済み)

Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19 (Correspondence)
 Doria-Rose N, Suthar MS, Makowski M, et al. 〔N Engl J Med. 2021 Apr 6〕(査読済み)

Delayed Localized Hypersensitivity Reactions to the Moderna COVID-19 Vaccine: A Case Series (Brief Report)
 Johnston MS, Galan A, Watsky KL, et al. 〔JAMA Dermatol. 2021 May 12〕(査読済み)